Home » though » Gilead reports early positive data in remdesivir studies as COVID-19 drug, though Chinese trial sees no benefit - MarketWatch

By Tuto Batod Wednesday, April 29, 2020 though

Gilead reports early positive data in remdesivir studies as COVID-19 drug, though Chinese trial sees no benefit - MarketWatch

Bagikan Berita Ini

0 Response to "Gilead reports early positive data in remdesivir studies as COVID-19 drug, though Chinese trial sees no benefit - MarketWatch"

Post a Comment

Subscribe to: Post Comments (Atom)